AI drug creation company Absci Corporation ( ABSI ) shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with Advanced Micro Devices Inc ( AMD ) to enhance its AI drug discovery capabilities.

The partnership will leverage AMD Instinct accelerators and ROCm software to support Absci’s advanced de novo antibody design models.

The deal also includes a $20 million private investment in public equity (PIPE) by AMD, underscoring the rising demand for AI applications in the pharmaceutical industry.

Absci ( ABSI ) aims to transform biologics development by utilizing optimized AI solutions that improve biological modeling. The partnership is expected to reduce infrastructure costs while accelerating innovation cycles.

Also Read: Uber And NVIDIA Partner On AI Technology For Autonomous Cars

AMD’s support will enable Absci ( ABSI ) to enhance its proprietary antibody design model, IgDesign1, which is the first in vitro validated inverse folding model for antibody design.

Sean McClain, Absci’s Founder and CEO, said, “AMD high-performance compute will enable us to further the development of next-generation antibody therapeutics, and we are excited about the potential that this partnership holds to accelerate the future of drug discovery.”

Price Action: ABSI shares are trading higher by 44.3% at $4.46 in premarket at the last check Wednesday.

Read Next:

AMD and Nvidia Overtake Intel in Key Markets, Challenging Its Leadership